ProfileGDS5678 / 1438025_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 73% 71% 71% 70% 70% 71% 72% 71% 70% 71% 73% 71% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7470662
GSM967853U87-EV human glioblastoma xenograft - Control 24.7621673
GSM967854U87-EV human glioblastoma xenograft - Control 34.4689271
GSM967855U87-EV human glioblastoma xenograft - Control 44.5364471
GSM967856U87-EV human glioblastoma xenograft - Control 54.4040170
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3367270
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4869971
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6049472
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4243771
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3875170
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4611971
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7960273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4160171
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6096672